Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Other Events

Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Other Events
Item 8.01 Other Events.

On April 18 2017, the Company issued a press release announcing interim results from its Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma and providing additional perspective on its decision to continue the ADAPT trial notwithstanding the recommendation of the trial’s Independent Data Monitoring Committee that the study be discontinued for futility. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On April 18, 2017, the Company will host a conference call to discuss the interim results of its ADAPT trial and to answer questions. The Company made available a slide presentation to accompany the call. A copy of the Company’s slide presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

The Exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.

 


About Argos Therapeutics, Inc. (NASDAQ:ARGS)

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Recent Trading Information

Argos Therapeutics, Inc. (NASDAQ:ARGS) closed its last trading session down -0.023 at 0.391 with 698,093 shares trading hands.

An ad to help with our costs